Ditchcarbon
  • Contact
  1. Organizations
  2. Sinco Pharma
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated 12 days ago

Sinco Pharma Sustainability Profile

Company website

Sinco Pharma, a leading player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2002, the company has established itself as a key provider of high-quality pharmaceutical products, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. With a commitment to innovation and quality, Sinco Pharma offers a diverse range of products, including generic medications and custom synthesis services, which are distinguished by their rigorous quality control and compliance with international standards. The company has achieved significant milestones, including certifications from major regulatory bodies, solidifying its market position as a trusted supplier in the global pharmaceutical landscape. Sinco Pharma continues to expand its reach, driven by a dedication to enhancing healthcare outcomes worldwide.

DitchCarbon Score

How does Sinco Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

26

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Sinco Pharma's score of 26 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.

47%

Let us know if this data was useful to you

Sinco Pharma's reported carbon emissions

In 2022, Sinco Pharma reported total carbon emissions of approximately 1,000,810 kg CO2e, encompassing Scope 1, 2, and 3 emissions. The breakdown includes about 93,260 kg CO2e from mobile combustion and 552,000 kg CO2e from fugitive emissions under Scope 1. Scope 2 emissions from purchased electricity amounted to approximately 171,420 kg CO2e. Additionally, Scope 3 emissions included about 64,170 kg CO2e from business travel and 2,860 kg CO2e from waste generated in operations. Despite these figures, Sinco Pharma has not disclosed any specific reduction targets or climate pledges. The emissions data is cascaded from its parent company, Sinco Pharmaceuticals Holdings Limited, indicating a corporate family relationship that influences its environmental reporting. Overall, while Sinco Pharma's emissions data provides insight into its carbon footprint, the absence of defined reduction initiatives highlights an area for potential improvement in its climate commitments.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2022
Scope 1
645,260
Scope 2
171,420
Scope 3
67,030

How Carbon Intensive is Sinco Pharma's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sinco Pharma's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Sinco Pharma's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sinco Pharma is in CN, which we do not have grid emissions data for.

Sinco Pharma's Scope 3 Categories Breakdown

Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 8% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 96% of Scope 3 emissions.

Top Scope 3 Categories

2022
Business Travel
96%
Waste Generated in Operations
4%

Sinco Pharma's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Sinco Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Sinco Pharma's Emissions with Industry Peers

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

CSL Behring (Australia) Pty Ltd

AU
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Baxter

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 3 days ago

Hualan Bio

CN
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Bruschettini Srl

IT
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy